₹21.95
(Market cap
₹2,884 Cr
Recently Viewed
Clear AllMarket cap
₹2,884 Cr
Revenue (TTM)
₹1,074 Cr
P/E Ratio
63.8
P/B Ratio
6
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹24 Cr
ROE
7.3 %
ROCE
8.8 %
Industry P/E
45.68
EV/EBITDA
23.7
Debt to Equity
1.5
Book Value
₹--
EPS
₹--
Face value
2
Shares outstanding
67,255,452
CFO
₹354.68 Cr
EBITDA
₹650.74 Cr
Net Profit
₹214.94 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Shasun Pharma
| 50.2 | 8.8 | 8.5 | 103.1 | 40.1 | 43.1 | 18.3 |
|
BSE Sensex*
| -9.5 | -2.9 | -9.0 | 3.2 | 8.6 | 9.0 | 12.0 |
|
BSE Healthcare#
| -2.4 | -2.6 | -3.9 | 5.9 | 24.1 | 13.8 | 10.8 |
|
Company
|
2014
|
|---|---|
|
Shasun Pharma
| 221.0 |
|
BSE Sensex
| 29.9 |
|
BSE Healthcare
| 47.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Shasun Pharma
|
428.6 | 2,884.3 | 1,074.4 | 44.7 | 7.6 | 10.3 | 63.8 | 6.0 |
| 2,322.1 | 19,001.9 | 1,215.1 | 284.8 | 28.7 | 21.1 | 66.2 | 12.5 | |
| 720.2 | 14,153.5 | 7,266.8 | 627.5 | 11.9 | 12.6 | 22.5 | 2.6 | |
| 635.5 | 15,741.3 | 5,092.5 | 545.5 | 15.9 | 14.1 | 28.9 | 3.6 | |
| 879.0 | 14,000.0 | 7,918.4 | 429.9 | 10.7 | 7.2 | 32.4 | 2.1 | |
| 1,123.7 | 20,140.0 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 12.9 | 2.3 | |
| 1,375.7 | 15,713.4 | 1,419.3 | 20.1 | 8.4 | 0.5 | 781.7 | 2.7 | |
| 143.0 | 18,995.0 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.4 | |
| 393.1 | 15,857.7 | 3,720.2 | 352.1 | 13.7 | 8.2 | 45 | 3.3 | |
| 1,369.7 | 22,276.9 | 3,151.0 | -10.0 | 8.4 | 2.5 | 1012.6 | 4.8 |
Sensex: The index which wouldn't grow up
2 min read•By Vikas Vardhan
Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable... alkaloids; Read more
Incorporated
1976
Chairman
R Kannan
Managing Director
S Abhaya Kumar
Headquarters
Chennai, Tamil Nadu
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsRecord Date for Scheme of Amalgamation
06-Nov-2015Shareholding Pattern for September 30, 2015
13-Oct-2015
The share price of Shasun Pharmaceuticals Ltd is ₹428.55 (NSE) and ₹428.85 (BSE) as of 17-Nov-2015 IST. Shasun Pharmaceuticals Ltd has given a return of 40.14% in the last 3 years.
The P/E ratio of Shasun Pharmaceuticals Ltd is 63.83 times as on 17-Nov-2015, a 40 premium to its peers’ median range of 45.68 times.
The P/B ratio of Shasun Pharmaceuticals Ltd is 5.99 times as on 17-Nov-2015, a 91 premium to its peers’ median range of 3.13 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2015
|
93.92
|
6.25
|
|
2014
|
13.26
|
1.33
|
|
2013
|
7.14
|
1.41
|
|
2012
|
4.58
|
2.11
|
|
2011
|
9.47
|
3.02
|
The 52-week high and low of Shasun Pharmaceuticals Ltd are Rs -- and Rs -- as of 09-Apr-2026.
Shasun Pharmaceuticals Ltd has a market capitalisation of ₹ 2,884 Cr as on 17-Nov-2015. As per SEBI classification, it is a company.
Before investing in Shasun Pharmaceuticals Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.